

# Facial onset sensory motor neuronopathy (FOSMN) syndrome: an unusual amyotrophic lateral sclerosis phenotype?

Steve Vucic<sup>1,2</sup>

Facial onset sensory and motor neuronopathy (FOSMN) syndrome may represent an amyotrophic lateral sclerosis phenotype as indicated by associated with the heterozygous D90A superoxide dismutase-1 (SOD-1) gene mutation.

Facial onset sensory and motor neuronopathy (FOSMN) syndrome is a rare and slowly progressive neurological disorder heralded by development of sensory symptoms within the face (trigeminal nerve distribution), and followed by evolution of sensory and motor deficits in a rostral-caudal direction.<sup>1</sup> The motor deficits are characterised by lower motor neurone features including muscle weakness and wasting, cramps and fasciculations, with absence of upper motor neurone signs.<sup>1 2</sup> The pathophysiological mechanisms underlying FOSMN syndrome remain to be fully elucidated, although neurodegenerative and autoimmune mechanisms have been proposed.<sup>1-5</sup>

Pathologic studies seem to support a neurodegenerative mechanism, with evidence of sensory and motor neuronal degeneration within the trigeminal sensory nucleus, dorsal root ganglion, brainstem and spinal cord motor nuclei along with an absence of tissue inflammation.<sup>1 2</sup> Of further relevance, immunomodulatory therapies seem to exert, at best, a moderate and non-sustained response, thereby further suggesting a predominant role for neurodegenerative processes in the pathogenesis of FOSMN syndrome. A link between FOSMN syndrome and amyotrophic lateral

sclerosis (ALS) has been recently suggested,<sup>3</sup> raising the prospect of establishing a potential mechanism of neurodegeneration. While some pathological studies have failed to document any features of ALS, including TAR DNA-binding protein 43 (TDP-43) intraneuronal inclusions, Bunina bodies or ubiquitin inclusions,<sup>1 2</sup> thereby arguing against an association, a recent study reported widespread TDP-43 inclusions with the implication being that FOSMN syndrome may represent a spectrum of motor neurone disease like TDP-43 proteinopathy syndromes.<sup>6</sup>

In the article by Dalla Bella<sup>7</sup> and colleagues, a heterozygous D90A mutation in the superoxide dismutase-1 (SOD-1) gene was reported in a single case of FOSMN syndrome and proposed as further evidence to suggest that FOSMN syndrome may be an unusual ALS phenotype. While the pathogenicity of the homozygous D90A SOD-1 mutation is well established,<sup>8</sup> that of the heterozygous D90A mutation is less certain, being detected in unaffected ALS family members<sup>9</sup> and co-occurring with other ALS related genetic mutations.<sup>10</sup> Importantly, the heterozygous D90A mutation may form part of an oligogenic pattern, which could result in unusual phenotypes under specific conditions. In contrast, the identification of non-ALS related genes in FOSMN syndrome, namely the oculopharyngeal muscular dystrophy trinucleotide repeat expansion,<sup>2</sup> may also argue for a chance association. The notion that FOSMN syndrome represents an unusual ALS phenotype remains to be established, and further genotype-phenotype studies incorporating larger numbers of FOSMN patients would be essential to establish any such associations.

**Contributors** SV wrote the editorial commentary.

**Competing interests** Dr Vucic has no competing interests.

**Provenance and peer review** Commissioned; internally peer reviewed.



**To cite** Vucic S. *J Neurol Neurosurg Psychiatry* 2014;**85**:951.

Received 13 February 2014

Accepted 25 February 2014

Published Online First 18 March 2014



► <http://dx.doi.org/10.1136/jnnp-2013-307416>

*J Neurol Neurosurg Psychiatry* 2014;**85**:951.  
doi:10.1136/jnnp-2014-307756

## REFERENCES

- Vucic S, Tian D, Chong PS, et al. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. *Brain* 2006;129:3384–90.
- Vucic S, Stein TD, Hedley-Whyte ET, et al. FOSMN syndrome: novel insight into disease pathophysiology. *Neurology* 2012;79:73–9.
- Fluchere F, Verschuere A, Cintas P, et al. Clinical features and follow-up of four new cases of facial-onset sensory and motor neuronopathy. *Muscle Nerve* 2011;43:136–40.
- Hokonohara T, Shigetou H, Kawano Y, et al. Facial onset sensory and motor neuronopathy (FOSMN) syndrome responding to immunotherapies. *J Neurol Sci* 2008;275:157–8.
- Isoardo G, Troni W. Sporadic bulbospinal muscle atrophy with facial-onset sensory neuropathy. *Muscle Nerve* 2008;37:659–62.
- Sonoda K, Sasaki K, Tateishi T, et al. TAR DNA-binding protein 43 pathology in a case clinically diagnosed with facial-onset sensory and motor neuronopathy syndrome: an autopsy case report and a review of the literature. *J Neurol Sci* 2013;332:148–53.
- Dalla Bella E, Rigamonti A, Mantero V, et al. Heterozygous D90A-SOD1 mutation in a patient with facial onset sensory motor neuronopathy (FOSMN) syndrome: a bridge to amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2014;**85**:1009–11.
- Andersen P. Amyotrophic lateral sclerosis genetics with Mendelian inheritance. In: Brown R Jr, Swash M, Pasinelli P, eds. *Amyotrophic Lateral Sclerosis*. 2nd ed. London: Informa Healthcare, 2006:187–207.
- Felbecker A, Camu W, Valdmanis PN, et al. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? *J Neurol Neurosurg Psychiatry* 2010;81:572–7.
- van Blitterswijk M, van Es MA, Hennekam EAM, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. *Hum Mol Gen* 2012;21:3776–84.

<sup>1</sup>Sydney Medical School Westmead, University of Sydney, Sydney, New South Wales, Australia;

<sup>2</sup>Neuroscience Research Australia, Sydney, New South Wales, Australia

**Correspondence to** Dr Steve Vucic, Sydney Medical School, Westmead, University of Sydney, Darcy and Hawkesbury Rd, Wentworthville, Sydney, NSW 2045 Australia; [s.vucic@neura.edu.au](mailto:s.vucic@neura.edu.au)



# Facial onset sensory motor neuronopathy (FOSMN) syndrome: an unusual amyotrophic lateral sclerosis phenotype?

Steve Vucic

*J Neurol Neurosurg Psychiatry* 2014 85: 951 originally published online March 18, 2014  
doi: 10.1136/jnnp-2014-307756

---

Updated information and services can be found at:  
<http://jnnp.bmj.com/content/85/9/951>

---

## References

*These include:*

This article cites 8 articles, 3 of which you can access for free at:  
<http://jnnp.bmj.com/content/85/9/951#BIBL>

## Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

## Topic Collections

Articles on similar topics can be found in the following collections

[Motor neurone disease](#) (287)  
[Neuromuscular disease](#) (1263)  
[Spinal cord](#) (515)  
[Drugs: CNS \(not psychiatric\)](#) (1860)  
[Musculoskeletal syndromes](#) (517)  
[Immunology \(including allergy\)](#) (1839)  
[Muscle disease](#) (246)

---

## Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>